GIVE LIFE TIME LIMITED

Sales & Support
Request A Quote - Email

Select Language

English
French
German
Italian
Russian
Spanish
Portuguese
Dutch
Greek
Japanese
Korean
Arabic
Hindi
Turkish
Indonesian
Vietnamese
Thai
Bengali
Persian
Polish

Home
Products
About Us
Factory Tour
Quality Control
Contact Us
Request A Quote
Shopping

Categories: All Categories

Chest Lung Cancer Drugs

Breast Cancer Drugs

Gastrointestinal Cancer Treatment

Blood Myeloma Lymphoma Drugs

Hepatobiliary Cancer Cirrhosis Hepatitis C Drugs

Pancreatic Cancer Drugs

Urogenital Cancer Drugs

Thrombocytopenia Treatment Drugs

Skin Endocrine Rheumatism Drugs

Genetic Testing Services

Genetic Testing Equipment

Medical Diagnostic Test Kits

Medical Rescue Drone

Home Products Skin Endocrine Rheumatism Drugs

60 Tablets 4mg Baricitinib Palutini-4 Rheumatoid Arthritis Drugs

All Products

Chest Lung Cancer Drugs (49)

Breast Cancer Drugs (18)

Gastrointestinal Cancer Treatment (11)

Blood Myeloma Lymphoma Drugs (23)

Hepatobiliary Cancer Cirrhosis Hepatitis C Drugs (17)

Pancreatic Cancer Drugs (1)

Urogenital Cancer Drugs (12)

Thrombocytopenia Treatment Drugs (7)

Skin Endocrine Rheumatism Drugs (9)

Genetic Testing Services (52)

Genetic Testing Equipment (3)

Medical Diagnostic Test Kits (8)

Medical Rescue Drone (5)

I'm Online Chat Now

Certification

60 Tablets 4mg Baricitinib Palutini-4 Rheumatoid Arthritis Drugs

Name: 60 Tablets 4mg Baricitinib Palutini-4 Rheumatoid Arthritis Drugs
Brand: Palutini
SKU: Palutini
Price: 55342706 USD
Availability: InStock
Rating: 4.6 (153 reviews)

Large Image : 60 Tablets 4mg Baricitinib Palutini-4 Rheumatoid Arthritis Drugs Get Best Price

Product Details:

Place of Origin:	Laos
Brand Name:	Palutini

Payment & Shipping Terms:

Minimum Order Quantity:	1 PCS
Price:	Please contact the specialist WhatsAApp：55342706 (open all year round)
Packaging Details:	Negotiable
Delivery Time:	Negotiable
Payment Terms:	T/T, Western Union, MoneyGram
Supply Ability:	Negotiable

Contact Now

Detailed Product Description

Specifications:	4mg*60 Tablets/bottle (box)	Indications:	Rheumatoid Arthritis (RA), Ankylosing Spondylitis (AS), Psoriasis, Atopic Dermatitis, Systemic Lupus Erythematosus, Ulcerative Colitis (UC), Alopecia Areata
Generic Name:	Baricitinib	Dosage:	Treatment With This Product Should Be Initiated And Supervised By A Physician Experienced In The Use Of Anticancer Drugs
Storage:	Store At No More Than 30℃.	Prescription Required:	Yes
Highlight:	4mg Skin Endocrine Rheumatism Drugs , 60 Tablets Skin Endocrine Rheumatism Drugs , 60 Tablet Skin Endocrine Rheumatism Drugs

Drug Name】

Generic name: baricitinib tablets

Product name: OLUMIANT®

English name: Baricitinib Tablets

Chinese Pinyin: Baruitini Pian

【Indications】

Rheumatoid Arthritis: Baricitinib is indicated for adult patients with moderately to severely active rheumatoid arthritis who have failed to respond to or are intolerant to one or more disease-modifying antirheumatic drugs (DMARDs). Baricitinib may be used in combination with methotrexate or other nonbiologic disease-modifying antirheumatic drugs.

Alopecia areata: Baricitinib is indicated for the treatment of severe alopecia areata in adults. Combination with other JAK inhibitors, biological immunomodulators, cyclosporine or other potent immunosuppressants is not recommended.

【Dosage】

Rheumatoid Arthritis

Treatment should be given by a doctor experienced in diagnosing and treating rheumatoid arthritis.

The recommended dose of baricitinib is 2 mg once daily.

For the following groups, 4 mg once daily administration may be considered: 1) For adult patients with moderately to severely active rheumatoid arthritis who have poor efficacy or intolerance to traditional disease-modifying antirheumatic drugs (csDMARDs), it is recommended to start treatment with 2 mg once daily Once daily, patients who still have poor efficacy after 3 months of treatment, or 2) patients who have poor efficacy of tumor necrosis factor inhibitors (TNFi-IR).

Alopecia areata

The recommended dose of baricitinib is 2 mg once daily.

If the response to treatment is insufficient, the dosage may be considered to be increased to 4 mg once daily.

For patients with nearly complete or complete alopecia, with or without extensive loss of eyelashes or eyebrows, a dose of 4 mg once daily may be considered.

When the patient achieves an adequate response to 4 mg of treatment, the dose should be reduced to 2 mg once daily.

kidney damage

For patients with creatinine clearance between 30 and 60 mL/minute, if the recommended dose of baricitinib is 4 mg once daily, reduce to 2 mg once daily. If the recommended dose of baricitinib is 2 mg, its use is not recommended;

Baricitinib is not recommended in patients with creatinine clearance <30 mL/minute.

liver damage

No dose adjustment is necessary in patients with mild or moderate hepatic impairment. The use of baricitinib is not recommended in patients with severe hepatic impairment.

Coadministration with OAT3 inhibitors

For patients receiving potent inhibitors of organic anion transporter 3 (OAT3), such as probenecid, if the recommended dose of baricitinib is 4 mg once daily, reduce it to 2 mg once daily; If the recommended dose of baricitinib is 2 mg once daily, the use of this product is not recommended.

Should not be initiated in patients with absolute lymphocyte count (ALC) less than 0.5  109 cells/L, absolute neutrophil count (ANC) less than 1  109 cells/L, or hemoglobin value less than 8 g/dL treat. Once values improve above these limits, treatment can be initiated.

It can be administered orally, with or without food, at any time of the day.

【Adverse reactions】

Summary of security features

The most common adverse drug reactions (ADRs) are increased low-density lipoprotein (LDL) cholesterol, upper respiratory tract infection, headache, herpes simplex, and urinary tract infection. Severe pneumonia and severe herpes zoster occasionally occur in patients with rheumatoid arthritis.

Adverse reaction list

Frequency estimates: Very common (≥ 1/10), Common (≥ 1/100 to < 1/10), Occasional (≥ 1/1,000 to < 1/100), Rare (≥ 1/10,000 to < 1/ 1,000), very rare (< 1/10,000). Frequencies in Table 1 are based on combined data from clinical trials and/or post-marketing sources for the rheumatoid arthritis, atopic dermatitis, and alopecia areata indications, unless otherwise stated. If significant frequency differences are observed among indications, these differences will be listed in footnotes below the table.

▼ Table 1: Adverse reactions

System organ classification Very common Common Occasionally

Infections and Infectious Diseases Upper Respiratory Infections

herpes zoster b

herpes simplex

Gastroenteritis

urinary tract infection

Infectious pneumoniad

Blood and Lymphatic System Disorders

Thrombocytosis > 600 x 109 cells/La,d Neutropenia < 1 x 109 cells/La

Metabolic and Nutritional Diseases Hypercholesterolemiaa

Hypertriglyceridemiaa

Various neurological diseases

Headache

Gastrointestinal system diseases

Disgusting

stomach ache

diverticulitis

Hepatobiliary system diseases

Elevated ALT level ≥ 3 x ULNa,d Elevated AST level ≥ 3 x ULNa,e

Skin and subcutaneous tissue diseases

rash, acnec

immune system diseases

facial swelling, hives

Respiratory, chest and mediastinal diseases

Pulmonary embolismf

Vascular and Lymphatic Diseases

deep vein thrombosisb

Various inspections

Elevated creatine phosphokinase levels > 5 x ULNa,c Weight gain

a Includes changes detected during laboratory monitoring (see below).

b Frequencies of herpes zoster and deep vein thrombosis are based on clinical trials of rheumatoid arthritis.

c In clinical trials for rheumatoid arthritis, acne and elevated creatine phosphokinase levels >5 × ULN occurred occasionally with frequency.

d In clinical trials in atopic dermatitis, nausea and ALT ≥3×ULN have occasionally occurred. In clinical trials of alopecia areata, abdominal pain has occasionally occurred. In clinical trials for atopic dermatitis and alopecia areata, infectious pneumonia and thrombocytosis >600×109 cells/L occurred occasionally.

e In alopecia areata clinical trials, the occurrence of AST ≥3×ULN is common.

f Frequency of pulmonary embolism based on rheumatoid arthritis and atopic dermatitis clinical trials.

[Medicine for pregnant and lactating women]

Pregnancy

Research has shown that the JAK/STAT pathway is related to cell adhesion and cell polarity, which may affect early embryonic development. There are insufficient data on the use of baricitinib in pregnant women. Animal studies show reproductive toxicity.

Baricitinib is contraindicated in use during pregnancy. Women of childbearing potential must use effective contraception during treatment and for at least 1 week after treatment. If a patient becomes pregnant while taking baricitinib, the patient should be informed of the possible risk to the fetus.

Lactation

It is unknown whether baricitinib/metabolites are excreted in human milk. Pharmacodynamic/toxicological data obtained from animal studies have shown that baricitinib is excreted in breast milk.

The risk to the neonate/infant cannot be excluded and baricitinib should not be used during lactation. The potential benefits of breastfeeding to the child and the potential benefits of treatment to the mother should be taken into consideration when deciding whether to discontinue breastfeeding or discontinue treatment with baricitinib.

fertility

Studies in animals have shown that baricitinib treatment may reduce fertility in female animals during treatment but did not affect spermatogenesis in male animals.

[Medicine for children]

The safety and efficacy of baricitinib in children and adolescents younger than 18 years have not been established.

【Medication for the Elderly】

Clinical experience in patients ≥75 years of age is very limited, and age ≥65 years or ≥75 years did not affect baricitinib exposure (Cmax and AUC).

【Storage】

Store at no more than 30℃.
60 Tablets 4mg Baricitinib Palutini-4 Rheumatoid Arthritis Drugs 0